Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

2

US Previously Marketed

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Calcium sensing receptor

2

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

3

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1954

1

2017

2

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Secondary hyperparathyroidism in adult patients with chronic kidney disease on hemodialysis

2

Pain

1

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

3

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

1

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

KAI Pharmaceuticals

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

3

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

3

ChEMBL

3

EPA CompTox

3

EVMPD

3

FDA UNII

3

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

CALCIUM HOMEOSTASIS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ANTI-PARATHYROID AGENTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Other anti-parathyroid agents

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

2

Salts, Hydrates, Esters, etc.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 3 of 3 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

ETELCALCETIDE

60ME133FJB

Export Data
Search for Structure

Status:

US Approved Rx (2017)

First approved in 2017

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Calcium sensing receptor

Conditions:

Secondary hyperparathyroidism in adult patients with chronic kidney disease on hemodialysis

Etelcalcetide (formerly velcalcetide, trade name Parsabiv) is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis. Etelcalcetide was approved (trade name Parsabiv) for the treatment of secondary ...

hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis in February, 2017. Etelcalcetide is a synthetic peptide calcium-sensing receptor agonist. It allosterically modulates the calcium-sensing receptor (CaSR). Etelcalcetide binds to the CaSR and enhances activation of the receptor by extracellular calcium. Activation of the CaSR on parathyroid chief cells decreases PTH secretion.

FLUROXENE

FO7JHA3G03

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1954

Class (Stereo):

CHEMICAL (ACHIRAL)

Conditions:

FLUROXENE (Fluoromar®) is a colorless, volatile liquid, which was used as an inhalational anesthetic.

ETELCALCETIDE HYDROCHLORIDE

72PT5993DU

Export Data
Search for Structure

Status:

US Approved Rx (2017)

First approved in 2017

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Calcium sensing receptor

Conditions:

Secondary hyperparathyroidism in adult patients with chronic kidney disease on hemodialysis

Etelcalcetide (formerly velcalcetide, trade name Parsabiv) is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis. Etelcalcetide was approved (trade name Parsabiv) for the treatment of secondary ...

hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis in February, 2017. Etelcalcetide is a synthetic peptide calcium-sensing receptor agonist. It allosterically modulates the calcium-sensing receptor (CaSR). Etelcalcetide binds to the CaSR and enhances activation of the receptor by extracellular calcium. Activation of the CaSR on parathyroid chief cells decreases PTH secretion.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1